Table 1 Baseline demographic and clinical characteristics of TDF-treated HIV/HBV co-infected patients
From: HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons
| Â | Â | 143 patients | 128 patients |
|---|---|---|---|
| Â | Â | Detectable HBV DNA | Undetectable HBV DNA |
Origin: | Caucasian | 121 (84Â %) | 88 (68Â %) |
| Â | African | 16 (11Â %) | 36 (28Â %) |
| Â | Asian | 10 (4Â %) | 4 (3Â %) |
Age in years (median) | (range) | 41 (23–73) | 40 (21–75) |
Sex | M:F | 122 (85Â %):21 (15Â %) | 101 (79Â %):27 (21Â %) |
CD4 count (median) | (range) | 295 (6–1143) | 326 (21–1512) |
HIV viremia (median) log10 cp/ml | (range) | 2.84 (0–6.08) | 1.74 (0–6.01) |
HIV treatment | on HAART | 82 (57Â %) | 84 (66Â %) |
|  | treatment naïve | 31 (22 %) | 15 (12 %) |
| Â | off HAART | 30 (21Â %) | 29 (23Â %) |
Hepatitis delta infection | positive | 9 | 4 |
| Â | negative | 17 | 8 |
| Â | missing data | 117 | 116 |
HCV coinfection | positive | 31 | 37 |
| Â | negative | 110 | 87 |
| Â | missing data | 2 | 4 |
ALT (median) IU/ml | (range) IU/ml | 47 (11–1020) | 32 (7–284) |
AST (median) IU/ml | (range) IU/ml | 35 (19–375) | 33 (14–135) |
INR (median) | (range) | 1 (0.9-2.6) | 1 (0.9-1.2) |
Total Bilirubin (median) umol/L | (range) | 9 (4–243) | 9 (2–30) |
|  | (range) | 39 (20–49) | 39 (32–52) |
|  | (range) | 77 (37–214) | 76 (41–150) |